These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37833459)

  • 1. HMGB1 Mediates Inflammation-Induced DMT1 Increase and Dopaminergic Neurodegeneration in the Early Stage of Parkinsonism.
    Liang T; Yang SX; Qian C; Du LD; Qian ZM; Yung WH; Ke Y
    Mol Neurobiol; 2024 Apr; 61(4):2006-2020. PubMed ID: 37833459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S-Nitrosylation of Divalent Metal Transporter 1 Enhances Iron Uptake to Mediate Loss of Dopaminergic Neurons and Motoric Deficit.
    Liu C; Zhang CW; Lo SQ; Ang ST; Chew KCM; Yu D; Chai BH; Tan B; Tsang F; Tai YK; Tan BWQ; Liang MC; Tan HT; Tang JY; Lai MKP; Chua JJE; Chung MCM; Khanna S; Lim KL; Soong TW
    J Neurosci; 2018 Sep; 38(39):8364-8377. PubMed ID: 30104344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ndfip1 attenuated 6-OHDA-induced iron accumulation via regulating the degradation of DMT1.
    Jia W; Xu H; Du X; Jiang H; Xie J
    Neurobiol Aging; 2015 Feb; 36(2):1183-93. PubMed ID: 25467637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
    Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M
    Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease.
    Salazar J; Mena N; Hunot S; Prigent A; Alvarez-Fischer D; Arredondo M; Duyckaerts C; Sazdovitch V; Zhao L; Garrick LM; Nuñez MT; Garrick MD; Raisman-Vozari R; Hirsch EC
    Proc Natl Acad Sci U S A; 2008 Nov; 105(47):18578-83. PubMed ID: 19011085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease.
    Sasaki T; Liu K; Agari T; Yasuhara T; Morimoto J; Okazaki M; Takeuchi H; Toyoshima A; Sasada S; Shinko A; Kondo A; Kameda M; Miyazaki I; Asanuma M; Borlongan CV; Nishibori M; Date I
    Exp Neurol; 2016 Jan; 275 Pt 1():220-31. PubMed ID: 26555088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration.
    Gao HM; Zhou H; Zhang F; Wilson BC; Kam W; Hong JS
    J Neurosci; 2011 Jan; 31(3):1081-92. PubMed ID: 21248133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular Zn
    Tamano H; Nishio R; Morioka H; Takeda A
    Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central high mobility group box-1 induces mechanical hypersensitivity with spinal microglial activation in a mouse model of hemi-Parkinson's disease.
    Sato F; Nakamura Y; Ma S; Kochi T; Hisaoka-Nakashima K; Wang D; Liu K; Wake H; Nishibori M; Morioka N
    Biomed Pharmacother; 2022 Jan; 145():112479. PubMed ID: 34915668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx.
    Song N; Jiang H; Wang J; Xie JX
    J Neurosci Res; 2007 Nov; 85(14):3118-26. PubMed ID: 17663481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    Zhang S; Wang XJ; Tian LP; Pan J; Lu GQ; Zhang YJ; Ding JQ; Chen SD
    J Neuroinflammation; 2011 Nov; 8():154. PubMed ID: 22053982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent.
    Jiang H; Song N; Xu H; Zhang S; Wang J; Xie J
    Cell Res; 2010 Mar; 20(3):345-56. PubMed ID: 20125122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells.
    Garrido-Gil P; Rodriguez-Pallares J; Dominguez-Meijide A; Guerra MJ; Labandeira-Garcia JL
    Exp Neurol; 2013 Dec; 250():384-96. PubMed ID: 24184051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin.
    Santoro M; Maetzler W; Stathakos P; Martin HL; Hobert MA; Rattay TW; Gasser T; Forrester JV; Berg D; Tracey KJ; Riedel G; Teismann P
    Neurobiol Dis; 2016 Jul; 91():59-68. PubMed ID: 26921471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminochrome Induces Neuroinflammation and Dopaminergic Neuronal Loss: A New Preclinical Model to Find Anti-inflammatory and Neuroprotective Drugs for Parkinson's Disease.
    De Araújo FM; Frota AF; de Jesus LB; Macedo TC; Cuenca-Bermejo L; Sanchez-Rodrigo C; Ferreira KMS; de Oliveira JVR; de Fatima Dias Costa M; Segura-Aguilar J; Costa SL; Herrero MT; Silva VDA
    Cell Mol Neurobiol; 2023 Jan; 43(1):265-281. PubMed ID: 34988761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
    Zhang JX; Zhou KG; Yin YX; Jin LJ; Tong WF; Guo J; Yu LH; Ye XC; Jiang M
    Exp Gerontol; 2023 Jan; 171():112037. PubMed ID: 36436758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
    Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
    Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.